SCHEMBL16697463

SCHEMBL16697463

N=C(NOC(=O)c1c(-c2ccccc2Cl)noc1Cc1ccccc1)c1ccc2c(c1)OCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
ALDH1A1 P00352 5/20 0.48
HPGD P15428 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
KDM4E B2RXH2 2/20 0.48
TSHR P16473 2/20 0.48
USP2 O75604 1/20 0.48
GLA P06280 1/20 0.48
HTT P42858 1/20 0.48
ATM Q13315 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GAA P10253 2/20 0.44
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
POLB P06746 2/20 0.39
ALOX12 P18054 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16698337 0.88 MEN1 (0.50) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697469 0.85 KMT2A (0.48) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697460 0.85 ADORA3 (0.53) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697464 0.85 ADORA3 (0.53) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16698073 0.83 KMT2A (0.47) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697704 0.82 LMNA (0.46) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697680 0.78 MAPT (0.43) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697577 0.75 LMNA (0.60) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16697358 0.74 RAB9A (0.49) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL16698339 0.73 ADORA3 (0.55) MAPTALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150133495-A1 Substituted Acyloxyamidines as HCV NS3/4A Inhibitors VIROCURA THERAPEUTICS INC (CA) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133495-A1 Substituted Acyloxyamidines as HCV NS3/4A Inhibitors EIF2AK2, GTF3C4, GTF3C1 MAPT 4607/4885ALDH1A1 1619/4885HPGD 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.